IL-6 Levels Predict Response to ECT in Depressive Disorder

Share this content:
IL-6 Levels Predict Response to ECT in Depressive Disorder
IL-6 Levels Predict Response to ECT in Depressive Disorder

TUESDAY, March 13, 2018 (HealthDay News) -- For patients with major depressive disorder, interleukin-6 (IL-6) may predict benefit from electroconvulsive therapy (ECT), according to a study published recently in the Journal of Clinical Psychiatry.

Jennifer L. Kruse, M.D., from the University of California at Los Angeles, and colleagues examined whether markers of inflammation predicted response to ECT in patients with treatment-resistant depression. Levels of C-reactive protein (CRP), IL-6, IL-8, and tumor necrosis factor α, and severity of depression symptoms (Montgomery-Asberg Depression Rating Scale [MADRS]) were assessed before ECT treatment, after the second ECT session, and at completion of the index treatment series in 29 patients.

The researchers found that there was a correlation for higher IL-6 levels at baseline, but not other inflammatory markers or clinical variables, with lower end-of-treatment MADRS score (P = 0.01). IL-6 remained a significant predictor of end-of treatment MADRS for women (P = 0.02), but not men (P = 0.1), when stratified by sex; CRP was a significant predictor for women (P = 0.04), but not men (P = 0.66). There were increases in CRP and IL-6 from baseline to the second ECT session (P < 0.01); levels returned to baseline at the end of treatment. These changes were not associated with MADRS score over the course of ECT.

"Levels of IL-6 prior to ECT treatment may be useful in identifying those depressed patients most likely to benefit from ECT treatment," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »